Literature DB >> 20610596

Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.

Didier Dewailly1, Pascal Pigny, Benoît Soudan, Sophie Catteau-Jonard, Christine Decanter, Edouard Poncelet, Alain Duhamel.   

Abstract

CONTEXT: It is still debated whether clinical and/or biological indices of hyperandrogenism (HA) should be present to qualify a patient as having polycystic ovary syndrome (PCOS). We hypothesized that excessive follicle number (FN) assessed by ovarian ultrasonography and/or serum anti-Müllerian hormone (AMH) concentrations may be used as surrogates for the classical markers of HA. DESIGN AND METHODS: Data were obtained from a database of clinical, hormonal, and ultrasound features that were consecutively recorded in 270 women with PCOS (defined using the Rotterdam Criteria) and 217 infertile nonhyperandrogenic normoovulatory women. These variables were submitted to principal component analysis, a multivariable statistical procedure that transforms a number of possibly correlated variables into a smaller number of uncorrelated variables called principal components (PC). Variables that aggregate in the same PC capture the same information.
RESULTS: In the control group, as expected, three independent PCs were identified: 1) the markers of the metabolic (i.e. insulin resistance) status; 2) those of the androgen status; and 3) those of the follicle status. In the PCOS group, the metabolic variables also aggregated in a first PC. Ovarian androgen and follicle markers aggregated in a second independent PC, with FN and serum AMH having the strongest correlation coefficients. A third PC summarized the adrenal contribution to the HA of PCOS. In both groups, the free androgen index correlated equally to the first and second PCs.
CONCLUSIONS: The similarity of the first PC between controls and PCOS supports the hypothesis that the metabolic anomaly of PCOS is neither intrinsic nor specific. Conversely, by gathering the androgen and follicle variables, the second PC in PCOS may be viewed as summarizing a specific ovarian anomaly. Because both FN and/or serum AMH were strongly correlated to the second PC along with androgens, they may be used equally as surrogates for the classical markers of ovarian HA. This reconciles the Rotterdam Consensus and other definitions for PCOS, especially in women having the Rotterdam PCOS phenotype without HA. We thus propose a simple strategy for the diagnosis of PCOS in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20610596     DOI: 10.1210/jc.2010-0334

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  37 in total

1.  Ovarian markers and irregular menses among women with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications study.

Authors:  C Kim; R S Miller; B H Braffett; Y Pan; V L Arends; A K Saenger; A Barnie; A V Sarma
Journal:  Clin Endocrinol (Oxf)       Date:  2018-01-26       Impact factor: 3.478

2.  Suspected ontogeny of a recently described hypo-androgenic PCOS-like phenotype with advancing age.

Authors:  Norbert Gleicher; Vitaly A Kushnir; Sarah K Darmon; Qi Wang; Lin Zhang; David F Albertini; David H Barad
Journal:  Endocrine       Date:  2018-01-06       Impact factor: 3.633

3.  Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients.

Authors:  Alice Albu; Serban Radian; Simona Fica; Carmen Gabriela Barbu
Journal:  Endocrine       Date:  2014-07-15       Impact factor: 3.633

Review 4.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

5.  Nesfatin-1 and other hormone alterations in polycystic ovary syndrome.

Authors:  Rulin Deniz; Bilgin Gurates; Suleyman Aydin; Husnu Celik; Ibrahim Sahin; Yakup Baykus; Zekiye Catak; Aziz Aksoy; Cihan Citil; Sami Gungor
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

Review 6.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

7.  An exploratory factor analysis of nutritional biomarkers associated with major depression in pregnancy.

Authors:  Lisa M Bodnar; Katherine L Wisner; James F Luther; Robert W Powers; Rhobert W Evans; Marcia J Gallaher; P K Newby
Journal:  Public Health Nutr       Date:  2011-12-08       Impact factor: 4.022

8.  Antimüllerian hormone as a risk factor for miscarriage in naturally conceived pregnancies.

Authors:  Brianna M Lyttle Schumacher; Anne Marie Z Jukic; Anne Z Steiner
Journal:  Fertil Steril       Date:  2018-06-02       Impact factor: 7.329

9.  Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features.

Authors:  Melissa Pawelczak; Lisa Kenigsberg; Sarah Milla; Ying-Hua Liu; Bina Shah
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

10.  Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism.

Authors:  Yi Li; Yun Ma; Xianghong Chen; Wenjun Wang; Yu Li; Qingxun Zhang; Dongzi Yang
Journal:  J Assist Reprod Genet       Date:  2012-08-11       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.